About US
Contact us
-
Germany bans 80 generic drugs trialled at GVK Biosciences facility in IndiaGermany has banned 80 generic drugs that had clinical trials performed by GVK Biosciences in India and found to be substandard. The ban by Germany's Federal Institute for Drugs and Medical Devices (B2014/12/12
-
Outcomes Based Healthcare secures £1m grant to transform diabetes careUK-based Outcomes Based Healthcare has secured a £1m match-funded grant from Innovate UK, to lead the drive towards a more personalised, data-driven approach to improving health outcomes in diab2014/12/11
-
SMC recommends GSK’s Incruse Ellipta to treat COPD within NHS ScotlandThe Scottish Medicines Consortium (SMC) has recommended GlaxoSmithKline's (GSK) Incruse Ellipta 55mcg (umeclidinium) to treat patients with chronic obstructive pulmonary (COPD) within NHS Scotland. T2014/12/11
-
Mylan announces U.S. launch of Celecoxib CapsulesMylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's Celebrex®Capsules, wh2014/12/11
-
Catalent Biomanufacturing Center of Excellence, Madison, Wisconsin, United States of AmericaCatalent Pharma Solutions opened a state-of-the-art bio-manufacturing centre of excellence in Madison, Wisconsin, US, in April 2013. Following the inauguration, Catalent relocated its operations and 82014/12/10
-
India’s Aurobindo acquires nutritional US supplement maker Natrol for $132.5mIndia-based Aurobindo Pharma has completed the acquisition of US-based nutritional supplement maker Natrol for $132.5m. Carried out through its wholly-owned subsidiary Aurobindo Pharma USA (APUSA), t2014/12/10
-
Pfizer establishes gene therapy unit for rare disease researchUS-based drugmaker Pfizer has established a gene therapy platform to investigate potential treatments for patients. The company aims to expand its rare disease research and development activities. P2014/12/10
-
November’s top stories: Actavis buys Allergan, antibiotics misunderstood in UKActavis signs agreement to buy Botox-maker Allergan for $66bn Ireland-based pharmaceutical company Actavis signed an agreement to acquire US-based Botox-maker Allergan for $66bn or $219 per share.2014/12/9
-
KKR agrees to buy significant minority stake in Arbor PharmaceuticalsNew York-based private equity firm KKR has agreed to buy a significant minority stake in specialty drugmaker Arbor Pharmaceuticals, in a bid to help drive continued growth. Financial terms of the tra2014/12/9
-
Merck plans to buy Cubist Pharmaceuticals for $8bnUS-based drugmaker Merck is reportedly planning to buy antibiotics maker Cubist Pharmaceuticals, in a deal valued at more than $8bn. Merck intends to pay $100 per share for Cubist, bringing the value2014/12/9